Enzolytics, Inc. is a drug development company. The Company is focused on commercializing its licensed proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases to include the additional contracted areas of sales, marketing and distribution of medical devices, medical testing and nutraceutical products. Its subsidiaries include BioClonetics lmmunotherapy, Inc. and Biogenysis, Inc.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
14/09/26	$0.000400	-.--%	3,539,335
11/09/26	$0.000400	-20.00%	2,929,632
10/09/26	$0.000500	-.--%	873,703
09/09/26	$0.000500	-.--%	761,398

Real-time OTC Markets

More quotes

Real-time OTC Markets 22:44:28 04/06/2026 +04			5-day change	1st Jan Change
0.000800 ^USD	-20.00%		+60.00%	+166.67%

31/07/24	Enzolytics, Inc. and the Bulgaria Academy of Sciences Initiate A Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/A Applications	CI
29/07/24	Enzolytics, Inc. Enters into Collaboration Agreement with Manufacturer Elimus Ltd	CI

Market Cap	132K 115K 108K 98.04K 184K 12.68M 185K 1.29M 497K 6.43M 497K 486K 20.51M	P/E 2009 *	-	P/E 2010	-0.29x
Enterprise Value	460K 398K 377K 341K 640K 44.12M 645K 4.5M 1.73M 22.37M 1.73M 1.69M 71.34M	EV / Sales 2009	325,315,067x	EV / Sales 2010	210,445,953x
Free-Float	100%	Yield 2009 *	-	Yield 2010	-

31/07/24	Enzolytics, Inc. and the Bulgaria Academy of Sciences Initiate A Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/A Applications	CI
29/07/24	Enzolytics, Inc. Enters into Collaboration Agreement with Manufacturer Elimus Ltd	CI
02/05/24	Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment LLC	CI
25/03/24	Enzolytics, Inc. Announces Board Changes	CI
25/03/24	Enzolytics, Inc Appoints Diana Zhabilov as Chief Financial Officer	CI
25/03/24	Enzolytics, Inc Appoints Steven Sharabura as Chief Executive Officer	CI
26/06/23	Enzolytics Offers Update on Virogentics, Inc ITV-1 African Project	CI
21/04/23	Enzolytics, Inc. Provides Update on Clinical Trials	CI
17/04/23	Biogenysis, Inc. & Virogentics, Inc. executed a non-binding term sheet to acquire Sagaliam Acquisition Corp. from Lighthouse Investment Partners, LLC, Enzolytics, Inc., Sagaliam Sponsor LLC, GLD Sponsor Member, LLC, AHG Equities LLC and others for $450 million in a reverse merger transaction.	CI
08/02/23	Enzolytics Announces Preliminary Results of GLP Toxicology Study for its anti-HIV Therapeutic ITV-1 and Production of ITV-1 for Initiation of Registration in Africa	CI
03/01/23	Enzolytics to Develop Feline Monoclonal Antibodies	CI
13/12/22	Enzolytics, Inc. Announces U.S. Distribution of IPF Immune(TM) and Progress in each of its Therapeutic Platforms	CI
16/11/22	Enzolytics, Inc. Announces Expansion of Production of Its Monoclonal Antibody Therapeutics and Marketing of IPF Immune	CI

05/08/24	Penny Stocks to Watch August 2024: SPZI, RJDG, HIRU, AABB more inside...	AQ
28/03/24	Stocks Under 5¢ Watch Now! CLNV, HNRC, HALB, ENZC, RSHN	AQ
12/03/24	RushNet (OTC: RSHN) and Royal Caridea Join Forces to Transform Aquaculture Harvesting Shrimp and more...SPZI, HALB, ENZC, HNRC	AQ
01/03/24	Stocks Under 5¢ To Watch Now! HNRC, HALB, ENZC, SNNC, SPZI	AQ
07/02/24	OTC Stocks to Watch in February: CLNV, HNRC, ENZC, GEVI, PBIO	AQ

Enzolytics, Inc. Stock

Stocks

ENZC

US2941121079

Biotechnology & Medical Research

Valuation: Enzolytics, Inc.

Chart: Enzolytics, Inc.

Latest news: Enzolytics, Inc.

Press Releases: Enzolytics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Enzolytics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 day	-20.00%
1 week	+60.00%
Current month	+33.33%
1 month	+33.33%
6 months	+128.57%
Current year	+166.67%

Manager	Title	Age	Since
Steven Sharabura CEO	Chief Executive Officer	-	21/03/2024
Diana Zhabilov DFI	Director of Finance/CFO	-	21/03/2024
Harry Zhabilov CEO	Chief Executive Officer	59	16/06/2017

Director	Title	Age	Since
Harry Zhabilov CHM	Chairman	59	19/03/2024
Lachezar Ivanov BRD	Director/Board Member	-	19/03/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENZOLYTICS, INC.	-20.00%	+60.00%	+100.00%	-97.94%	1.93M
WUXI APPTEC CO., LTD.	-1.38%	+2.23%	+48.54%	+100.96%	70.24B
ARGENX SE	-1.04%	-0.81%	+34.61%	+75.16%	62.63B
INSMED INCORPORATED	-4.86%	-4.95%	-17.07%	+346.11%	27.36B
WUXI BIOLOGICS (CAYMAN) INC.	+0.16%	+1.53%	+34.92%	+17.47%	25.71B
BIONTECH SE	-1.53%	-1.43%	-0.64%	-13.98%	24.83B
GENMAB A/S	+1.61%	-0.69%	+20.85%	-19.42%	19.52B
PHARMAESSENTIA CORPORATION	+1.26%	-9.06%	+165.21%	+308.08%	15.51B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-3.91%	-5.71%	-8.71%	+521.92%	14.66B
SUMMIT THERAPEUTICS INC.	-5.84%	-0.64%	-9.35%	+818.18%	14.69B
Average	-3.55%	-1.20%	+36.84%	+205.65%	27.52B
Weighted average by Cap.	-1.53%	-0.64%	+31.61%	+165.16%

	2009	2010
Net sales	0.01 0.01 0.01 0.01 0.02 1.41 0.02 0.14 0.06 0.72 0.06 0.05 2.28	0.04 0.03 0.03 0.03 0.05 3.55 0.05 0.36 0.14 1.8 0.14 0.14 5.73
Net income	-970K -840K -794K -719K -1.35M -93.03M -1.36M -9.48M -3.65M -47.17M -3.64M -3.56M -150M	-7.51M -6.51M -6.15M -5.57M -10.46M -721M -10.54M -73.44M -28.26M -365M -28.22M -27.6M -1.17B
Net Debt	924K 800K 757K 685K 1.29M 88.61M 1.3M 9.03M 3.47M 44.93M 3.47M 3.39M 143M	328K 284K 268K 243K 456K 31.43M 459K 3.2M 1.23M 15.94M 1.23M 1.2M 50.83M